ArticleOncoimmunology
NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 57 citations in OpenAlex.
- A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL.Blood advances · 2023Trial
- Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma.Blood advances · 2021Trial
- PolyoxidoniumFrontiers in immunology · 2019Trial
- Emerging Immune Cell Biomarkers in Primary Membranous Nephropathy: Immune Cell Profiling During Anti-CD20 B Cell-Targeted Therapy.International journal of molecular sciences · 2026Review
- Review
- The Role of Chemokine-Related Genes in Diffuse Large B-Cell Lymphoma Prognosis and Tumor Microenvironment Characteristics.Analytical cellular pathology (Amsterdam) · 2026Article
- Predicting the risk of ibrutinib in combination with R-ICE in patients with relapsed or refractory DLBCL using explainable machine learning algorithms.Clinical and experimental medicine · 2025Article
- Increased TIGIT expression correlates with impaired NK cell function in diffuse large B-cell lymphoma.Frontiers in oncology · 2025Article
- Natural Killer cells at the frontline in the fight against cancer.Cell death & disease · 2024Review
- Identification of a novel form of caspase-independent cell death triggered by BH3-mimetics in diffuse large B-cell lymphoma cell lines.Cell death & disease · 2024Article
- Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma.Transplantation and cellular therapy · 2024Article
- NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells.Frontiers in immunology · 2023Article
- Article
- Article
- Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.Journal of translational medicine · 2022Article
- Prospects in the management of patients with follicular lymphoma beyond first-line therapy.Haematologica · 2022Article
- The use of tafasitamab in diffuse large B-cell lymphoma.Therapeutic advances in hematology · 2021Review
- Article
- Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance.Scientific reports · 2020Article
- Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obinutuzumab (OBZ) shows stronger antibody-dependent cell cytotoxicity (ADCC) compared to rituximab and improved clinical activity for treating certain CD20
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.